PMH42 COST-EFFECTIVENESS ANALYSIS OF OLANZAPINE LONG-ACTING INJECTION COMPARED WITH RISPERIDONE LONG-ACTING INJECTION IN THE TREATMENT OF SCHIZOPHRENIA IN NORWAY
Oct 1, 2009, 00:00
10.1016/S1098-3015(10)74761-6
https://www.valueinhealthjournal.com/article/S1098-3015(10)74761-6/fulltext
Title :
PMH42 COST-EFFECTIVENESS ANALYSIS OF OLANZAPINE LONG-ACTING INJECTION COMPARED WITH RISPERIDONE LONG-ACTING INJECTION IN THE TREATMENT OF SCHIZOPHRENIA IN NORWAY
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)74761-6&doi=10.1016/S1098-3015(10)74761-6
First page :
Section Title :
Open access? :
No
Section Order :
687